Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/169241
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Rojas, Elizabeta A. | - |
dc.contributor.author | Corchete, Luis A. | - |
dc.contributor.author | San-Segundo, Laura | - |
dc.contributor.author | Martínez-Blanch, Juan F. | - |
dc.contributor.author | Codoñer, Francisco M. | - |
dc.contributor.author | Paíno, Teresa | - |
dc.contributor.author | Puig, Noemi | - |
dc.contributor.author | García-Sanz, Ramón | - |
dc.contributor.author | Mateos, Maria Victoria | - |
dc.contributor.author | Ocio, Enrique M. | - |
dc.contributor.author | Misiewicz-Krzeminska, Irena | - |
dc.contributor.author | Gutiérrez, Norma Carmen | - |
dc.date.accessioned | 2018-08-30T07:42:13Z | - |
dc.date.available | 2018-08-30T07:42:13Z | - |
dc.date.issued | 2017 | - |
dc.identifier | doi: 10.1158/1078-0432.CCR-17-0678 | - |
dc.identifier | e-issn: 1557-3265 | - |
dc.identifier | issn: 1078-0432 | - |
dc.identifier.citation | Clinical Cancer Research 23(21): 6602-6615 (2017) | - |
dc.identifier.uri | http://hdl.handle.net/10261/169241 | - |
dc.description.abstract | [Purpose]: The search for new drugs that control the continuous relapses of multiple myeloma is still required. Here, we report for the first time the potent antimyeloma activity of amiloride, an old potassium-sparing diuretic approved for the treatment of hypertension and edema due to heart failure. [Experimental Design]: Myeloma cell lines and primary samples were used to evaluate cytotoxicity of amiloride. In vivo studies were carried out in a xenograft mouse model. The mechanisms of action were investigated using RNA-Seq experiments, qRT-PCR, immunoblotting, and immunofluorescence assays. [Results]: Amiloride-induced apoptosis was observed in a broad panel of multiple myeloma cell lines and in a xenograft mouse model. Moreover, amiloride also had a synergistic effect when combined with dexamethasone, melphalan, lenalidomide, and pomalidomide. RNA-Seq experiments showed that amiloride not only significantly altered the level of transcript isoforms and alternative splicing events, but also deregulated the spliceosomal machinery. In addition, disruption of the splicing machinery in immunofluorescence studies was associated with the inhibition of myeloma cell viability after amiloride exposure. Although amiloride was able to induce apoptosis in myeloma cells lacking p53 expression, activation of p53 signaling was observed in wild-type and mutated TP53 cells after amiloride exposure. On the other hand, we did not find a significant systemic toxicity in mice treated with amiloride. [Conclusions]: Overall, our results demonstrate the antimyeloma activity of amiloride and provide a mechanistic rationale for its use as an alternative treatment option for relapsed multiple myeloma patients, especially those with 17p deletion or TP53 mutations that are resistant to current therapies. | - |
dc.description.sponsorship | This study was partially supported by the Instituto de Salud Carlos III-Cofinanciacion with funding from FEDER (PI13/00111 and PI16/01074), Asociacion Española Contra el Cancer (AECC, GCB120981SAN), Gerencia Regional de Salud, Junta de Castilla y Leon (BIO/SA57/13 and BIO/SA22/15), and the INNOCAMPUS Program (CEI10-1-0010). I. Misiewicz-Krzeminska was supported by a Black Swan R esearch Initiative grant from the International Myeloma Foundation. L.A. Corchete was supported by a grant from the Fundacion Española de Hematología y Hemoterapia. | - |
dc.publisher | American Association for Cancer Research | - |
dc.rights | closedAccess | - |
dc.title | Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-17-0678 | - |
dc.date.updated | 2018-08-30T07:42:13Z | - |
dc.description.version | Peer Reviewed | - |
dc.language.rfc3066 | eng | - |
dc.contributor.funder | Asociación Española Contra el Cáncer | - |
dc.contributor.funder | Junta de Castilla y León | - |
dc.contributor.funder | International Myeloma Foundation | - |
dc.contributor.funder | Fundacion de la Sociedad Española de Hematología y Hemoterapia | - |
dc.contributor.funder | European Commission | - |
dc.contributor.funder | Instituto de Salud Carlos III | - |
dc.relation.csic | Sí | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/100003887 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100014180 | es_ES |
dc.identifier.pmid | 28790111 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
14
checked on 15-abr-2024
SCOPUSTM
Citations
24
checked on 19-abr-2024
WEB OF SCIENCETM
Citations
23
checked on 29-feb-2024
Page view(s)
330
checked on 19-abr-2024
Download(s)
115
checked on 19-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.